The National Pharmaceutical Pricing Authority (NPPA) has fixed the ceiling price of 51 drug formulations. This includes linagliptin-metformin hydrochloride tablets, which is a combination drug used to treat high blood sugar levels caused by type 2 diabetes. Another combination drug, rosuvastatin-clopidogrel, used to prevent heart attack and stroke, also has a capped price. The pricing authority has set the retail prices for specific dosages of these drugs. The NPPA has warned that manufacturers or marketing companies failing to comply with the pricing may be liable to pay fines as per the Drugs (Prices Control) Order 2013. In a separate move, the NPPA has also extended the ceiling price fixation for orthopaedic knee implants for another year, in an effort to make them more affordable for patients.